Metabolic surgery for type 2 diabetes in patients with a BMI of <35 kg/m2: A surgeon's perspective

Obesity Surgery

Volumn 23, Issue 6, 2013, Pages 809-818

  Cohen, Ricardo ^a   Caravatto, Pedro Paulo ^a   Petry, Tarissa ^a  

^a Forensic Toxicology Laboratory   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; AMYLIN DERIVATIVE; ANTIDIABETIC AGENT; DIPEPTIDYL PEPTIDASE IV INHIBITOR; HEMOGLOBIN A1C; INSULIN DERIVATIVE; ORAL ANTIDIABETIC AGENT; ROSIGLITAZONE;

BARIATRIC SURGERY; BILIOPANCREATIC BYPASS; BLADDER CANCER; BODY MASS; CALORIC RESTRICTION; CARDIOVASCULAR DISEASE; CHRONIC KIDNEY DISEASE; CLINICAL EFFECTIVENESS; COMORBIDITY; CORONARY ARTERY BYPASS GRAFT; DIABETES CONTROL; DIABETIC PATIENT; DIET RESTRICTION; DISEASE ASSOCIATION; DISEASE SEVERITY; DRUG SAFETY; DUODENOJEJUNAL BYPASS; DYSLIPIDEMIA; ENDOCRINE SURGERY; EPIDEMIC; FRACTURE; GASTRIC BANDING; GLUCOSE HOMEOSTASIS; HUMAN; HYPERTENSION; ILEAL TRANSPOSITION; INSULIN RESISTANCE; INSULIN SENSITIVITY; INTESTINE SURGERY; LACTIC ACIDOSIS; LIFESTYLE MODIFICATION; METABOLIC PARAMETERS; METABOLIC SURGERY; MORTALITY; NON INSULIN DEPENDENT DIABETES MELLITUS; NONALCOHOLIC FATTY LIVER; NONHUMAN; OBESITY; PANCREATITIS; PRIORITY JOURNAL; REMISSION; REVIEW; RISK BENEFIT ANALYSIS; ROUX Y ANASTOMOSIS; SLEEVE GASTRECTOMY; STOMACH BYPASS; SURGEON; SURGICAL TECHNIQUE; THYROID CANCER; TREATMENT INDICATION; WEIGHT REDUCTION;

BARIATRIC SURGERY; BLOOD GLUCOSE; BODY MASS INDEX; BRAZIL; DIABETES MELLITUS, TYPE 2; FEMALE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; MALE; OBESITY, MORBID; PATIENT SELECTION; REMISSION INDUCTION; RISK ASSESSMENT; TREATMENT OUTCOME; WEIGHT LOSS;

EID: 84878020543     PISSN: 09608923     EISSN: 17080428     Source Type: Journal    
DOI: 10.1007/s11695-013-0930-2     Document Type: Review

References (135)

1. Murray P, Chune GW, Raghavan VA. Legacy effects from DCCT and UKPDS: what they mean and implications for future diabetes trials. Curr Atheroscler Rep. 2010;12(6):432-9.
2. Gaede P, Vedel P, Larsen N, et al. Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med. 2003;348(5):383-93.
3. Grant RW, Buse JB, Meigs JB, et al. Quality of diabetes care in U.S. academic medical centers: low rates of medical regimen change. Diabetes Care. 2005;28(2):337-42.
4. DeFronzo RA, Abdul-Ghani M. Type 2 diabetes can be prevented with early pharmacological intervention. Diabetes Care. 2011;34 Suppl 2:S202-9.
5. Sjöström L, Peltonen M, Jacobson P, et al. Bariatric surgery and long-term cardiovascular events. JAMA. 2012;307(1):56-65.
6. Sjöström L, Narbro K, Sjöström CD, et al. Effects of bariatric surgery on mortality in Swedish obese subjects. N Engl J Med. 2007;357(8):741-52.
7. Shah SS, Todkar JS, Shah PS, et al. Diabetes remission and reduced cardiovascular risk after gastric bypass in Asian Indians with body mass index. Surg Obes Relat Dis. 2010;6(4):332-8.
8. Cohen RV, Rubino F, Schiavon C, et al. Diabetes remission without weight loss after duodenal bypass surgery. Surg Obes Relat Dis. 2011;8(5):66-8.
9. Cohen RV, Schiavon CA, Pinheiro Filho JC, et al. Laparoscopic bariatric surgery: new technologies, trends and perspectives. Rev Hosp Clin Fac Med Sao Paulo. 2003;58(5):I-VIII.
10. Geloneze B, Geloneze SR, Chaim E, et al. Metabolic surgery for non-obese type 2 diabetes: incretins, adipocytokines, and insulin secretion/resistance changes in a 1-year interventional clinical controlled study. Ann Surg. 2012;256(1):72-8.
11. DePaula AL, Macedo ALV, Rassi N, et al. Laparoscopic treatment of type 2 diabetes mellitus for patients with a body mass index less than 35. Surg Endosc. 2007;22(3):706-16.
12. Cummings DE, Flum DR. Gastrointestinal surgery as a treatment for diabetes. JAMA: The Journal of the American Medical Association. 2008;299(3):341-3.
13. Rubino F. Is type 2 diabetes an operable intestinal disease? A provocative yet reasonable hypothesis. Diabetes Care. 2008;31:S290-6.
14. Pories WJ, Dohm LG, Mansfield CJ. Beyond the BMI: the search for better guidelines for bariatric surgery. Obesity (Silver Spring). 2009;18(5):865-71.
15. Sjöström L, Lindroos A-K, Peltonen M, et al. Lifestyle, diabetes, and cardiovascular risk factors 10 years after bariatric surgery. N Engl J Med. 2004;351(26):2683-93.
16. Jahangiri Noudeh Y, Hadaegh F, Vatankhah N, et al. Wrist circumference as a novel predictor of diabetes and prediabetes: results of cross-sectional and 8.8-year follow-up studies. J Clin Endocrinol Metab. 2013;98:777-84.
17. Stefan N, Kantartzis K, Machann J, et al. Identification and characterization of metabolically benign obesity in humans. Arch Intern Med. 2008;168(15):1609-16.
18. Stefan N, Haring H-U. The metabolically benign and malignant fatty liver. Diabetes. 2011;60(8):2011-7.
19. Fabbrini E, Magkos F, Mohammeda BS, et al. Intrahepatic fat, not visceral fat, is linked with metabolic complications of obesity. PNAS. 2009;106(36):15430-5.
20. Targher G, Byrne CD. Nonalcoholic fatty liver disease: a novel cardiometabolic risk factor for type 2 diabetes and its complications. J Clin Endocrinol Metab. 2013;98(2):483-95.
21. Isbell JM, Tamboli RA, Hansen EN, et al. The importance of caloric restriction in the early improvements in insulin sensitivity after Roux-en-Y gastric bypass surgery. Diabetes Care. 2010;33(7):1438-42.
22. Anderson JW, Konz EC, Frederich RC, et al. Long-term weight-loss maintenance: a meta-analysis of US studies. Am J Clin Nutr. 2001;74(5):579-84.
23. Sumithran P, Prendergast LA, Delbridge E, et al. Long-term persistence of hormonal adaptations to weight loss. N Engl J Med. 2011;365(17):1597-604.
24. Rubino F. Bariatric surgery: effects on glucose homeostasis. Curr Opin Clin Nutr Metab Care. 2006;9:497-507.
25. Rubino F, Marescaux J. Effect of duodenal-jejunal exclusion in a non-obese animal model of type 2 diabetes: a new perspective for an old disease. Ann Surg. 2004;239:1-11.
26. 2: a report of 2 cases. Surg Obes Relat Dis. 2007;3(2):195-7.
27. Cohen R, Caravatto PP, Correa JL, et al. Glycemic control after stomach-sparing duodenal-jejunal bypass surgery in diabetic patients with low body mass index. Surg Obes Relat Dis. 2012;8(4):375-80.
28. Pournaras DJ, Osborne A, Hawkins SC, et al. Remission of type 2 diabetes after gastric bypass and banding: mechanisms and 2 year outcomes. Ann Surg. 2010;252(6):966-71.
29. Laferrère B, Teixeira J, McGinty J, et al. Effect of weight loss by gastric bypass surgery versus hypocaloric diet on glucose and incretin levels in patients with type 2 diabetes. J Clin Endocrinol Metab. 2008;93(7):2479-85.
30. Wickremesekera K, Miller G, Naotunne TD, et al. Loss of insulin resistance after Roux-en-Y gastric bypass surgery: a time course study. Obes Surg. 2005;15(4):474-81.
31. Kashyap SR, Daud S, Kelly KR, et al. Acute effects of gastric bypass versus gastric restrictive surgery on β-cell function and insulinotropic hormones in severely obese patients with type 2 diabetes. Int J Obes. 2010;34:462-71.
32. Garrido-Sanchez L, Murri M, Rivas-Becerra J, et al. Bypass of the duodenum improves insulin resistance much more rapidly than sleeve gastrectomy. SOARD. American Society for Metabolic and Bariatric Surgery. 2011;8(2):145-50.
33. Cummings DE. Gastric bypass and nesidioblastosis - too much of a good thing for islets? N Engl J Med. 2005;353(3):300-2.
34. Service GJ, Thompson GB, Service FJ, et al. Hyperinsulinemic hypoglycemia with nesidioblastosis after gastric-bypass surgery. N Engl J Med. 2005;353(3):249-54.
35. Goldfine AB, Mun EC, Devine E, et al. Patients with neuroglycopenia after gastric bypass surgery have exaggerated incretin and insulin secretory responses to a mixed meal. J Clin Endocrinol Metab. 2007;92(12):4678-85.
36. McLaughlin T, Peck M, Holst J, et al. Reversible hyperinsulinemic hypoglycemia after gastric bypass: a consequence of altered nutrient delivery. J Clin Endocrinol Metab. 2010;95(4):1851-5.
37. Cohen RV, Pinheiro JC, Schiavon CA, et al. Effects of gastric bypass surgery in patients with type 2 diabetes and only mild obesity. Diabetes Care. 2012;35(7):1420-8.
38. Klein S, Fabbrini E, Patterson BW, et al. Moderate effect of duodenal-jejunal bypass surgery on glucose homeostasis in patients with type 2 diabetes. Obesity (Silver Spring). 2009;20(6):1266-72.
39. Lee W-J, Chong K, Ser K-H, et al. Gastric bypass vs sleeve gastrectomy for type 2 diabetes mellitus: a randomized controlled trial. Arch Surg. 2011;146(2):143-8.
40. Umeda LM, Silva EA, Carneiro G, et al. Early improvement in glycemic control after bariatric surgery and its relationships with insulin, GLP-1, and glucagon secretion in type 2 diabetic patients. Obes Surg. 2011;21(7):896-901.
41. Dixon JB, O'Brien PE, Playfair J, et al. Adjustable gastric banding and conventional therapy for type 2 diabetes: a randomized controlled trial. JAMA. 2008;299(3):316-23.
42. 2: an integrative review of early studies. Obes Surg. 2010;20(6):776-90.
43. Chiellini C, Rubino F, Castagneto M, et al. The effect of bilio-pancreatic diversion on type 2 diabetes in patients with BMI. Diabetologia. 2009;52(6):1027-30.
44. Franco JVA, Ruiz PA, Palermo M, et al. A review of studies comparing three laparoscopic procedures in bariatric surgery: sleeve gastrectomy, Roux-en-Y gastric bypass and adjustable gastric banding. Obes Surg. 2011;21(9):1458-68.
45. Bohdjalian A, Langer FB, Shakeri-Leidenmühler S, et al. Sleeve gastrectomy as sole and definitive bariatric procedure: 5-year results for weight loss and ghrelin. Obes Surg. 2010;20(5):535-40.
46. 2). Surg Obes Relat Dis. 2010;5(4):425-8.
47. Lee W-J, Ser K-H, Chong K, et al. Laparoscopic sleeve gastrectomy for diabetes treatment in nonmorbidly obese patients: efficacy and change of insulin secretion. Surgery. 2010;147(5):664-9.
48. Pories WJ, Swanson MS, MacDonald KG, et al. Who would have thought it? An operation proves to be the most effective therapy for adult-onset diabetes mellitus. Ann Surg. 1995;222(3):339-50. discussion 350-2.
49. Schauer PR, Burguera B, Ikramuddin S. Effect of laparoscopic Roux-en Y gastric bypass on type 2 diabetes mellitus. Ann Surg. 2003;238:467-85.
50. Buchwald H, Avidor Y, Braunwald E, et al. Bariatric surgery: a systematic review and meta-analysis. JAMA: The Journal of the American Medical Association. 2004;292(14):1724-37.
51. Cohen R, Pinheiro JS, Correa JL, et al. Laparoscopic Roux-en-Y gastric bypass for BMI. Surg Obes Relat Dis. 2006;2(3):401-4. discussion 404.
52. 2. Pol Przegl Chir. 2011;83(2):81-6.
53. 2. Obes Surg. 2011;21(3):283-7.
54. 2. J Gastrointest Surg. 2008;12(5):945-52.
55. Schauer PR, Kashyap SR, Wolski K, et al. Bariatric surgery versus intensive medical therapy in obese patients with diabetes. N Engl J Med. 2012;366(17):1567-76.
56. Scopinaro N, Adami GF, Papadia FS, et al. Effects of biliopanceratic diversion on type 2 diabetes in patients with BMI 25 to 35. Ann Surg. 2011;253(4):699-703.
57. Patriti A, Facchiano E, Annetti C, et al. Early improvement of glucose tolerance after ileal transposition in a non-obese type 2 diabetes rat model. Obes Surg. 2005;15(9):1258-64.
58. Cummings BP, Strader AD, Stanhope KL, et al. Ileal interposition surgery improves glucose and lipid metabolism and delays diabetes onset in the UCD-T2DM rat. Gastroenterology. 2010;138(7):2437-46. 2446.e1.
59. Strader AD, Clausen TR, Goodin SZ, et al. Ileal interposition improves glucose tolerance in low dose streptozotocin-treated diabetic and euglycemic rats. Obes Surg. 2008;19(1):96-104.
60. Kumar KH, Ugale S, Gupta N, et al. Ileal interposition with sleeve gastrectomy for control of type 2 diabetes. Diabetes Technol Ther. 2009;11(12):785-9.
61. Kota SK, Ugale S, Gupta N, et al. Ileal interposition with sleeve gastrectomy for treatment of type 2 diabetes mellitus. Indian J Endocrinol Metab. 2012;16(4):589-98.
62. de Paula AL, Macedo ALV, Prudente AS, et al. Laparoscopic sleeve gastrectomy with ileal interposition ("neuroendocrine brake") - pilot study of a new operation. SOARD. 2006;2(4):464-7.
63. Tinoco A, El-Kadre L, Aquiar L, et al. Short-term and mid-term control of type 2 diabetes mellitus by laparoscopic sleeve gastrectomy with ileal interposition. World J Surg. 2011;35(10):2238-44.
64. 2. Surg Obes Relat Dis. 2011;6(3):296-304.
65. Kota SK, Ugale S, Gupta N, et al. Laparoscopic ileal interposition with diverted sleeve gastrectomy for treatment of type 2 diabetes. Diabetes Metab Syndr. 2012;6(3):125-31.
66. Rubino F, Forgione A, Cummings DE, et al. The mechanism of diabetes control after gastrointestinal bypass surgery reveals a role of the proximal small intestine in the pathophysiology of type 2 diabetes. Ann Surg. 2006;244(5):741-9.
67. Speck M, Cho YM, Asadi A, et al. Duodenal-jejunal bypass protects GK rats from {beta}-cell loss and aggravation of hyperglycemia and increases enteroendocrine cells coexpressing GIP and GLP-1. AJP: Endocrinology and Metabolism. 2011;300(5):E923-32.
68. Breen DM, Rasmussen BA, Kokorovic A, et al. Jejunal nutrient sensing is required for duodenal-jejunal bypass surgery to rapidly lower glucose concentrations in uncontrolled diabetes. Nat Med. 2012;18:950-5.
69. Gavin TP, Sloan RC, Lukosius EZ, et al. Duodenal-jejunal bypass surgery does not increase skeletal muscle insulin signal transduction or glucose disposal in Goto-Kakizaki type 2 diabetic rats. Obes Surg. 2011;21(2):231-7.
70. Wang Y, Zhang Z-Z, Wang L, et al. [Effect of blood glucose control after small intestine exclusion surgery in Goto-Kakizaki rat with type 2 diabetes mellitus]. Zhonghua Yi Xue Za Zhi. 2009;89(40):2858-61.
71. Geloneze B, Geloneze SR, Fiori C, et al. Surgery for nonobese type 2 diabetic patients: an interventional study with duodenal-jejunal exclusion. Obes Surg. 2009;19(8):1077-83.
72. 2. Obes Surg. 2009;19:307-12.
73. Cohen RV, Neto MG, Correa JL, et al. A pilot study of the duodenal-jejunal bypass liner in low body mass index type 2 diabetes. J Clin Endocrinol Metab. 2013;98:E279-82.
74. Yamaoka K, Tango T. Efficacy of lifestyle education to prevent type 2 diabetes: a meta-analysis of randomized controlled trials. Diabetes Care. 2005;28(11):2780-6.
75. Li Q, Chen L, Yang Z, et al. Metabolic effects of bariatric surgery in type 2 diabetic patients with body mass index. Diabetes Obes Metab. 2011;14(3):262-70.
76. Look AHEAD, Group R, Wing RR. Long-term effects of a lifestyle intervention on weight and cardiovascular risk factors in individuals with type 2 diabetes mellitus: four-year results of the Look AHEAD Trial. Arch Intern Med. 2010;170(17):1566-75.
77. Gregg EW, Chen H, Wagenknecht LE, et al. Association of an intensive lifestyle intervention with remission of type 2 diabetes. JAMA. 2012;308(23):2489-96.
78. Arterburn DE, Bogart A, Sherwood NE, et al. A multisite study of long-term remission and relapse of type 2 diabetes mellitus following gastric bypass. Obes Surg. 2012;23(1):93-102.
79. Arterburn DE, O'Connnor PJ. A look ahead at the future of diabetes prevention and treatment. JAMA. 2012;308:2517-8.
80. Dixon JB, Zimmet P, Alberti KG, et al. Bariatric surgery: an IDF statement for obese type 2 diabetes. Diabet Med. 2011;28:628-42.
81. Nathan DM. Finding new treatments for diabetes - how many, how fast. how good? N Engl J Med. 2007;356:437-40.
82. Nathan DM, Buse JB, Davidson MB, et al. Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care. 2009;32(1):193-203.
83. De Valk HW. DPP-4 inhibitors and combined treatment in type 2 diabetes: re-evaluation of clinical success and safety. Rev Diabet Stud. 2007;4:126-33.
84. Donekal S, Shomali ME. Effectiveness of the novel anti-diabetes medication exenatide in everyday practice: comparison with clinical trials. Diabetes Res Clin Pract. 2008;80(2):e4-6.
85. Pratley RE, Kipnes MS, Fleck PR, et al. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor alogliptin in patients with type 2 diabetes inadequately controlled by glyburide monotherapy. Diabet Obes Metab. 2009;11(2):167-76.
86. Polonsky KS. The past 200 years in diabetes. N Engl J Med. 2012;367(14):1332-40.
87. Amori RE, Lau J, Pittas AG. Efficacy and safety of incretin therapy in type 2 diabetes: systematic review and meta-analysis. JAMA. 2007;298(2):194-206.
88. Sinha A, Rajan M, Hoerger T, et al. Costs and consequences associated with newer medications for glycemic control in type 2 diabetes. Diabetes Care. 2010;33(4):695-700.
89. Lautz D, Halperin F, Goebel-Fabbri A, et al. The great debate: medicine or surgery: what is best for the patient with type 2 diabetes? Diabetes Care. 2011;34(3):763-70.
90. Dixon JB, Schachter LM, O'Brien PE, et al. Surgical vs conventional therapy for weight loss treatment of obstructive sleep apnea: a randomized controlled trial. JAMA. 2012;308(11):1142-9.
91. Gaede P, Lund-Andersen H, Parving H-H, et al. Effect of a multifactorial intervention on mortality in type 2 diabetes. N Engl J Med. 2008;358(6):580-91.
92. Romeo S, Maglio C, Burza MA, et al. Cardiovascular events after bariatric surgery in obese subjects with type 2 diabetes. Diabetes Care. 2012;35(12):2613-7.
93. Christou NV, Sampalis JS, Liberman M, et al. Surgery decreases long-term mortality, morbidity, and health care use in morbidly obese patients. Ann Surg. 2004;240(3):416-24.
94. Psaty BM, Furberg CD. Rosiglitazone and cardiovascular risk. N Engl J Med. 2007;356(24):2522-4.
95. Home PD, Pocock SJ, Beck-Nielsen H, et al. Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trial. Lancet. 2009;373(9681):2125-35.
96. Nissen SE, Wolski K. Rosiglitazone revisited: an updated meta-analysis of risk for myocardial infarction and cardiovascular mortality. Arch Intern Med. 2010;170:1191-201.
97. Sarafidis PA, Lasaridis AN, Nilsson PM, et al. The effect of rosiglitazone on novel atherosclerotic risk factors in patients with type 2 diabetes mellitus and hypertension. Metabolism. 2005;54(9):1236-42.
98. Diamond GA, Bax L, Kaul S. Uncertain effects of rosiglitazone on the risk for myocardial infarction and cardiovascular death. Ann Intern Med. 2007;147(8):578-81.
99. Nissen SE, Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med. 2007;356(24):2457-71.
100. Singh S, Loke YK, Furberg CD. Long-term risk of cardiovascular events with rosiglitazone: a meta-analysis. JAMA. 2007;298(10):1189-95.
101. Wei L, Macdonald TM, Mackenzie IS. Pioglitazone and bladder cancer: a propensity score matched cohort study. Br J Clin Pharmacol. 2013;75(1):254-9.
102. Govindan J, Evans M. Pioglitazone in clinical practice: where are we now? Diabetes Ther. 2012;3(1):1-8.
103. Piccinni C, Motola D, Marchesini G, et al. Assessing the association of pioglitazone use and bladder cancer through drug adverse event reporting. Diabetes Care. 2011;34(6):1369-71.
104. Zhu Z, Shen Z, Lu Y, et al. Increased risk of bladder cancer with pioglitazone therapy in patients with diabetes: a meta-analysis. Diabetes Res Clin Pract. 2012;98(1):159-63.
105. Aubert RE, Herrera V, Chen W, et al. Rosiglitazone and pioglitazone increase fracture risk in women and men with type 2 diabetes. Diabet Obes Metab. 2010;12(8):716-21.
106. Song SO, Kim KJ, Lee B-W, et al. The risk of bladder cancer in Korean diabetic subjects treated with pioglitazone. Diabetes Metab J. 2012;36(5):371-8.
107. Ferrara A, Lewis JD, Quesenberry CP, et al. Cohort study of pioglitazone and cancer incidence in patients with diabetes. Diabetes Care. 2011;34:923-9.
108. Kopec KT, Kowalski MJ. Metformin-associated lactic acidosis (MALA): case files of the Einstein Medical Center Medical Toxicology Fellowship. J Med Toxicol. 2013;9:61-6.
109. Cicero AFG, Tartagni E, Ertek S. Metformin and its clinical use: new insights for an old drug in clinical practice. Arch Med Sci. 2012;8(5):907-17.
110. Salpeter SR, Greyber E, Pasternak GA, et al. Risk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitus: systematic review and meta-analysis. Arch Intern Med. 2003;163(21):2594-602.
111. Kajbaf F, Lalau J-D. The criteria for metformin-associated lactic acidosis: the quality of reporting in a large pharmacovigilance database. Diabet Med. 2013;30:345-8.
112. Dixit A, Pandey P. Rosiglitazone and pioglitazone. Beware fractures. BMJ. 2009;339:b3957.
113. Douglas IJ, Evans SJ, Pocock S, et al. The risk of fractures associated with thiazolidinediones: a self-controlled case-series study. PLoS Med. 2009;6(9):e1000154.
114. Mamtani R, Haynes K, Bilker WB, et al. Association between longer therapy with thiazolidinediones and risk of bladder cancer: a cohort study. J Natl Cancer Inst. 2012;104(18):1411-21.
115. Lee PH, Stockton MD, Franks AS. Acute pancreatitis associated with liraglutide. Ann Pharmacother. 2011;45(4):e22-2.
116. Alves C, Batel-Marques F, Macedo AF. A meta-analysis of serious adverse events reported with exenatide and liraglutide: acute pancreatitis and cancer. Diabetes Res Clin Pract. 2012;98(2):271-84.
117. Sternthal E. Incretin-based therapy and pancreatitis - what is the risk? Endocr Pract. 2011;17:334-6.
118. Anderwald C-H, Tura A, Promintzer-Schifferl M, et al. Alterations in gastrointestinal, endocrine, and metabolic processes after bariatric Roux-en-Y gastric bypass surgery. Diabetes Care. 2012;35(12):2580-7.
119. Elashoff M, Matveyenko AV, Gier B, et al. Pancreatitis, pancreatic, and thyroid cancer with glucagon-like peptide-1-based therapies. YGAST (Internet). 2011;141(1):150-6.
120. Parks M, Rosebraugh C. Weighing risks and benefits of liraglutide - the FDA's review of a new antidiabetic therapy. N Engl J Med. 2010;362(9):774-7.
121. Shukla AP, Ahn SM, Patel RT, et al. Surgical treatment of type 2 diabetes: the surgeon perspective. Endocrine. 2011;40(2):151-61.
122. Wolfe BM, Morton JM. Weighing in on bariatric surgery: procedure use, readmission rates, and mortality. JAMA. 2005;294(15):1960-3.
123. DeMaria EJ, Pate V, Warthen M, et al. Baseline data from American Society for Metabolic and Bariatric Surgery-designated Bariatric Surgery Centers of Excellence using the Bariatric Outcomes Longitudinal Database. Surg Obes Relat Dis. 2010;6:347-55.
124. Maciejewski ML, Winegar DA, Farley JF, et al. Risk stratification of serious adverse events after gastric bypass in the Bariatric Outcomes Longitudinal Database. Surg Obes Relat Dis. 2012;8(6):671-7.
125. Pories WJ. Bariatric surgery: risks and rewards. J Clin Endocrinol Metab. 2008;93(11-Supplement-1):89-96.
126. Pratt GM, McLees B, Pories WJ. The ASBS Bariatric Surgery Centers of Excellence program: a blueprint for quality improvement. Surg Obes Relat Dis. 2006;2(5):497-503.
127. DeMaria EJ, Winegar DA, Pate VW, et al. Early postoperative outcomes of metabolic surgery to treat diabetes from sites participating in the ASMBS Bariatric Surgery Center of Excellence Program as reported in the Bariatric Outcomes Longitudinal Database. Ann Surg. 2010;252(3):559-66.
128. Bal BS, Finelli FC, Shope TR, et al. Nutritional deficiencies after bariatric surgery. Nat Rev Endocrinol. 2012;8(9):544-56.
129. Davies DJ, Baxter JM, Baxter JN. Nutritional deficiencies after bariatric surgery. Obes Surg. 2007;17(9):1150-8.
130. Rubino F, Schauer PR, Kaplan LM. Metabolic surgery to treat type 2 diabetes: clinical outcomes and mechanisms of action. Ann Rev Med. 2010;61:393-411.
131. Madan AK. Metabolic surgery: not just weight loss surgery anymore. Surg Obes Relat Dis. 2009;5(1):18-9.
132. Mingrone G, Panunzi S, De Gaetano A, et al. Bariatric surgery versus conventional medical therapy for type 2 diabetes. N Engl J Med. 2012;366(17):1577-85.
133. Rubino F, Kaplan LM, Schauer PR, et al. The Diabetes Surgery Summit Consensus Conference. Ann Surg. 2010;251(3):399-405.
134. American Diabetes Association. Standards of medical care in diabetes - 2013. Diabetes Care. 2013;36 Suppl 1:11-66.
135. Zimmet P, Alberti KGM, Rubino F, et al. IDF's view of bariatric surgery in type 2 diabetes. Lancet. 2011;378(9786):108-10.